Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs State Street SPDR S&P Biotech ETF — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $27.68, while State Street SPDR S&P Biotech ETF trades at $152. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals.
| FNGU | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $36.15 | $164.28 |
52-Week Low | $13.73 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a leveraged ETN tracking the FANG+ Index, trades at $28.79, down 0.38% on the day. Technical indicators show mixed signals with moving averages bullish but oscillators bearish, including overbought RSI readings above 80. Recent performance highlights extreme volatility, with a documented 16% single-session drop on June 5, 2026, illustrating the amplified risks of its 3x leverage structure.
The outlook for FNGU is highly speculative, driven entirely by momentum in its underlying tech stocks rather than traditional fundamentals. Investment opportunity exists for aggressive traders betting on continued tech sector strength, but risks are severe, including decay from daily resets and catastrophic losses during market downturns, as recent news demonstrates.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
